OptiNose Files Q1 2025 10-Q
| Field | Detail |
|---|---|
| Company | Optinose, Inc. |
| Form Type | 10-Q |
| Filed Date | May 14, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, pharmaceutical
TL;DR
OptiNose Q1 2025 10-Q filed. Financials out.
AI Summary
OptiNose, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the first quarter of 2025. Key financial data and business segments are presented, with the company's principal executive offices located in Yardley, PA.
Why It Matters
This filing provides investors with the latest financial snapshot of OptiNose, Inc., crucial for understanding the company's performance and outlook in the pharmaceutical sector.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, OptiNose faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 267-364-3500 — Business Phone (Contact information for OptiNose, Inc.)
Key Players & Entities
- OptiNose, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of the reporting period
- 20250514 (date) — Filing date
- Yardley, PA (location) — Company's business address
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is the quarter ended March 31, 2025.
When was this 10-Q filed with the SEC?
This 10-Q was filed on May 14, 2025.
What is the principal business of OptiNose, Inc.?
OptiNose, Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).
Where are OptiNose, Inc.'s principal executive offices located?
OptiNose, Inc.'s principal executive offices are located at 777 Township Line Road, Suite 300, Yardley, PA 19067.
What is the SEC file number for OptiNose, Inc.?
The SEC file number for OptiNose, Inc. is 001-38241.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 14, 2025 regarding OptiNose, Inc..